Get the Stockscreener App
4.96
0.61%
0.03
Precision Biosciences Inc stock is traded at $4.96, with a volume of 11,101.
It is up +0.61% in the last 24 hours and down -1.59% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.93
Open:
$4.95
24h Volume:
11,101
Relative Volume:
0.05
Market Cap:
$58.46M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-7.5152
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+3.77%
1M Performance:
-1.59%
6M Performance:
+9.49%
1Y Performance:
-45.55%
1-Day Range:
$4.9401
$5.03
1-Week Range:
$4.75
$5.16
52-Week Range:
$3.61
$9.8131
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.96 | 58.11M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.11 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.24 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.57 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
715.54 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.05 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Brown Melinda buys $6846 in Precision BioSciences (DTIL) By Investing.com - Investing.com Nigeria
Brown Melinda buys $6846 in Precision BioSciences (DTIL) - Investing.com India
Insider Buying: Melinda Brown Acquires Shares in Precision BioSc - GuruFocus
Risk Recap: How does Precision BioSciences Inc correlate with Nasdaq2025 Technical Overview & Precise Swing Trade Alerts - خودرو بانک
Layoff Tracker: Arvinas Downsizes by 15% After Punting Pfizer-Partnered Asset - BioSpace
Candlestick signals on Precision BioSciences Inc. stock today2025 Year in Review & Growth Oriented Trade Recommendations - newser.com
Published on: 2025-09-18 07:24:27 - newser.com
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
AI Stocks: What is the long term forecast for Precision BioSciences Inc. stockWeekly Profit Report & Long-Term Capital Growth Strategies - خودرو بانک
ARCUS Gene Editor Shows Promise Against Hepatitis B - CRISPR Medicine News
Surprises Report: Is Precision BioSciences Inc stock trending bullish2025 Momentum Check & Target Return Focused Picks - خودرو بانک
Insider Buy: Whats the outlook for Precision BioSciences Incs sectorJuly 2025 Pullbacks & High Conviction Investment Ideas - خودرو بانک
Is Precision BioSciences Inc likely to announce a buyback2025 Market Trends & Reliable Intraday Trade Alerts - خودرو بانک
Published on: 2025-09-16 12:16:08 - newser.com
Is Precision BioSciences Inc. building a consolidation baseTrade Analysis Summary & Free Fast Gain Swing Trade Alerts - newser.com
Nasdaq Moves: What is the long term forecast for Precision BioSciences Inc stockStop Loss & Weekly Market Pulse Alerts - خودرو بانک
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium - BioSpace
Transcript : Precision BioSciences, Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-09-2025 10 - MarketScreener
Sectors Review: Is Precision BioSciences Inc a speculative investmentJuly 2025 Snapshot & Real-Time Volume Trigger Notifications - خودرو بانک
What momentum shifts mean for Precision BioSciences Inc.Take Profit & Weekly High Potential Alerts - newser.com
Stock Analysis: Does BNTX offer margin of safetyPortfolio Update Summary & Stock Portfolio Risk Management - خودرو بانک
Smart tools for monitoring Precision BioSciences Inc.’s price actionMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Reversal indicators forming on Precision BioSciences Inc. stockPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
How to integrate Precision BioSciences Inc. into portfolio analysis tools2025 Valuation Update & Stepwise Entry and Exit Trade Signals - newser.com
When is the best time to exit Precision BioSciences Inc.M&A Rumor & AI Based Trade Execution Alerts - newser.com
Precision BioSciences Inc. stock volume spike explainedWatch List & Safe Entry Point Identification - newser.com
What MACD signals say about Precision BioSciences Inc.July 2025 Trends & Community Verified Trade Signals - newser.com
Precision BioSciences presents data from hepatitis B gene editing trial By Investing.com - Investing.com Australia
Can Precision BioSciences Inc. hit a new high this monthGlobal Markets & Free High Return Stock Watch Alerts - Newser
Is Precision BioSciences Inc. stock poised for growthWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial - Contract Pharma
Will Precision BioSciences Inc. bounce back from current supportTreasury Yields & AI Powered Market Entry Strategies - Newser
Custom strategy builders for tracking Precision BioSciences Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th Inte - PharmiWeb.com
Precision BioSciences presents phase 1 PBGENE-HBV trial data at HBV Cure Symposium; targets chronic hepatitis B - MarketScreener
Precision BioSciences presents data from hepatitis B gene editing trial - Investing.com
Statistical indicators supporting Precision BioSciences Inc.’s strengthJuly 2025 Chart Watch & Advanced Technical Analysis Signals - Newser
Risk adjusted return profile for Precision BioSciences Inc. analyzedJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - Newser
Will Precision BioSciences Inc. price bounce be sustainableTrade Entry Report & Reliable Price Breakout Signals - Newser
Top chart patterns to watch in Precision BioSciences Inc.July 2025 Highlights & Reliable Breakout Forecasts - Newser
Will Precision BioSciences Inc. continue its uptrendEarnings Overview Report & Daily Profit Maximizing Trade Tips - Newser
What MACD and RSI say about Precision BioSciences Inc.2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Comparing Precision BioSciences Inc. in custom built stock radarsMarket Growth Review & Free AI Powered Buy and Sell Recommendations - Newser
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly John Alexander | Chief Financial Officer |
Jul 03 '25 |
Sale |
4.26 |
14,827 |
63,163 |
73,485 |
0.54%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):